APA način citiranja

Ku, B. M., Bae, Y., Koh, J., Sun, J., Lee, S., Ahn, J. S., . . . Ahn, M. (2017). Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget.

Čikaški stil citiranja

Ku, Bo Mi, Yeon-Hee Bae, Jiae Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, i Myung-Ju Ahn. "Mutational Status of TP53 Defines the Efficacy of Wee1 Inhibitor AZD1775 in KRAS-mutant Non-small Cell Lung Cancer." Oncotarget 2017.

MLA način citiranja

Ku, Bo Mi, et al. "Mutational Status of TP53 Defines the Efficacy of Wee1 Inhibitor AZD1775 in KRAS-mutant Non-small Cell Lung Cancer." Oncotarget 2017.